Applied BioMath, LLC Announces Presentations in Dual Sessions at ACoP9

News provided by

Sep 25, 2018, 15:47 ET

CONCORD, Mass., Sept. 25, 2018 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation in two speaking sessions at ACoP9 occurring October 7-10, 2018 in San Diego, CA.

Joshua Apgar, PhD, Co-Founder and CSO, Applied BioMath and Tarek Leil, PhD, Bristol Myers Squibb, are co-chairing Session 4C: Parameter Variability is Not a Crime: Virtual Patients Simulations with Quantitative Systems Pharmacology (QSP) Model Tuesday, October 9, 2018 from 2:15-3:45pm.

As a conceptual overview to Session 4C, Dr. Apgar is presenting a talk titled "Parameter uncertainty and inter-individual variability as two sources of parameter variability for QSP model." This presentation reviews various approaches for estimating uncertainties of QSP model prediction following model calibration with data from a mixture of preclinical (in vitro and in vivo) and clinical (PK and PD) studies. Dr. Apgar will also review how model sensitivity analysis can be used to relate parametric uncertainty to output uncertainty, and various approaches for generating virtual patient populations. A QSP model for Alzheimer's Disease will serve as an example for various analysis.

Concurrently, John Burke, PhD, Co-Founder, President and CEO, Applied BioMath is participating in Session 4A: Model-based Solutions to Complexities in Developing Drugs Exhibiting Target-mediated Drug Disposition (TMDD) being chaired by Scott A. Van Wart, PhD, Enhanced Pharmacodynamics. As part of the session Dr. Burke is presenting a talk titled "Integrating TMDD and QSP models to accelerate the development of biological immunotherapy." Dr. Burke's talk describes the development and application of a coupled TMDD and QSP model to guide the development of antibody-based immunotherapy targeting PD-1 and TIM-3 receptors. The final model provides new insights into the biological system and is useful for identifying lead compound(s) and accelerating their development.

"We are thrilled to be selected to present at ACoP9 this year," said John Burke, PhD, Co-Founder, President and CEO, Applied BioMath. "As new trends emerge in QSP modeling, it's important to convene and present new findings and best practices."

In addition to presenting during two conference sessions, Applied BioMath will have a booth and exhibit five posters throughout the conference. For more information about Applied BioMath's presence at ACoP9, visit https://www.appliedbiomath.com/news-resources/events/acop9.

For more information about all of Applied BioMath's upcoming events, visit www.appliedbiomath.com/news-resources/events.

About Applied BioMath

Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.

Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
[email protected]

SOURCE Applied BioMath, LLC